FisherVista

Canamera Energy Metals Corp. is advancing its rare earth projects in Brazil with new exploration and a technical report, highlighting the growing strategic importance of rare earth elements for the global economy.

MindWave Innovations Inc. (NYSE American: APUS) offers a secure and compliant gateway to digital assets, addressing the growing need for corporate treasury infrastructure to responsibly hold, report, and deploy bitcoin and other digital assets.

Cheqroom introduces AssetOps, a strategic framework aimed at unifying IT, facilities, and finance asset management to reduce operational risks and costs.

Veraxa Biotech has expanded its laboratory space in Heidelberg, Germany, to support the growth of its R&D team and advance its proprietary BiTAC platform toward clinical development for cancer therapies.

Oncotelic Therapeutics Inc. is expanding beyond its oncology roots into AI and pharmaceutical automation by partnering with TechForce Robotics to commercialize a GMP-compliant, AI-enhanced robotics platform.

222 Websites has expanded its custom website design and local SEO services to six West Virginia cities, addressing a gap in digital marketing support for small businesses across the state.

Demand & Convert announced a proprietary web architecture designed to help local home service contractors build organic visibility and control their own lead pipeline, reducing reliance on third-party directories that force price competition.

LakeShore Biopharma has finalized its merger with Oceanpine Skyline Inc., becoming a private entity and ceasing public trading, with shareholders receiving $0.066 per share.

VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data for its BiTAC-ADC platform, showing selective destruction of cancer cells while sparing healthy cells, as it prepares for strategic discussions at the BIO International Convention 2026.

Greenland Energy Company advances the Jameson Land Basin toward exploration drilling, with CEO Robert Price highlighting potential 13 billion barrels and a targeted October 2026 campaign.

Onco-Innovations is pushing forward with its lead nanomedicine candidate ONC010, leveraging a polymer delivery system to improve drug retention and tolerability, as the broader field of cancer nanomedicine sees renewed promise with over 20 approved formulations.

Gold and silver prices have risen sharply, with gold reaching $4,362 an ounce and silver hitting $71.2 an ounce, driven by key market factors that could boost investor interest in mining companies like New Pacific Metals Corp.

Quantum BioPharma advances its first-in-class drug candidate Lucid-MS into phase 2 clinical trials, aiming to directly repair the myelin sheath destroyed by multiple sclerosis, a disease affecting over 2.9 million people worldwide with no cure.

Researchers from King’s College London and McMaster University have discovered a molecular pathway critical for cancer migration to the brain, potentially revolutionizing metastatic disease treatment.

A new study indicates that excessive dependence on AI tools like ChatGPT and Claude could impair critical thinking and independent judgment, with implications for industries such as gaming where companies like Core AI Holdings Inc. are integrating AI into product design.

A new wave of DNA Damage Response inhibitors, including Onco-Innovations' ONC010, is expanding beyond PARP inhibitors, targeting a $7 billion market in 2025 and a projected $750 billion oncology sector by 2030.

Functional beverages are moving beyond specialty stores and fitness culture into everyday routines, driven by consumer demand for clean ingredients, convenience, and integration into daily habits.

Quantum BioPharma is progressing its novel drug candidate Lucid-MS, which directly protects myelin sheaths, toward Phase 2 trials, potentially transforming MS treatment by targeting neuroprotection rather than immune modulation.

Beeline Holdings Inc. (NASDAQ: BLNE) has been added to the Russell Microcap Index, highlighting its growth in digital mortgage lending with AI-enabled underwriting and a focus on gig-economy borrowers and home equity access.

Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, in the $7 billion DNA damage response oncology market, with preclinical success and partnerships positioning it for future clinical trials.

Cardio Diagnostics Holdings announced that Atlas Healthcare Physicians will provide coverage for its Epi+Gen CHD and PrecisionCHD tests, expanding access to noninvasive blood-based diagnostics for coronary heart disease risk assessment and diagnosis.